X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Merck Ltd with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

MERCK LTD vs IPCA LABS - Comparison Results

MERCK LTD    Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    MERCK LTD IPCA LABS MERCK LTD/
IPCA LABS
 
P/E (TTM) x 49.0 28.3 173.1% View Chart
P/BV x 7.4 3.4 220.5% View Chart
Dividend Yield % 0.4 0.1 273.4%  

Financials

 MERCK LTD   IPCA LABS
EQUITY SHARE DATA
    MERCK LTD
Dec-16
IPCA LABS
Mar-18
MERCK LTD/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs1,060695 152.4%   
Low Rs623400 155.8%   
Sales per share (Unadj.) Rs632.4260.2 243.1%  
Earnings per share (Unadj.) Rs45.719.0 241.0%  
Cash flow per share (Unadj.) Rs62.333.1 188.5%  
Dividends per share (Unadj.) Rs11.001.00 1,100.0%  
Dividend yield (eoy) %1.30.2 715.9%  
Book value per share (Unadj.) Rs388.8213.0 182.5%  
Shares outstanding (eoy) m16.60126.20 13.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.32.1 63.2%   
Avg P/E ratio x18.428.9 63.8%  
P/CF ratio (eoy) x13.516.6 81.5%  
Price / Book Value ratio x2.22.6 84.2%  
Dividend payout %24.15.3 456.5%   
Avg Mkt Cap Rs m13,96969,120 20.2%   
No. of employees `0001.613.3 11.9%   
Total wages/salary Rs m1,4877,359 20.2%   
Avg. sales/employee Rs Th6,631.92,477.4 267.7%   
Avg. wages/employee Rs Th939.2555.2 169.2%   
Avg. net profit/employee Rs Th479.4180.6 265.4%   
INCOME DATA
Net Sales Rs m10,49832,836 32.0%  
Other income Rs m242418 58.0%   
Total revenues Rs m10,74133,254 32.3%   
Gross profit Rs m1,1354,505 25.2%  
Depreciation Rs m2761,777 15.5%   
Interest Rs m0240 0.0%   
Profit before tax Rs m1,1022,905 37.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m343511 67.2%   
Profit after tax Rs m7592,394 31.7%  
Gross profit margin %10.813.7 78.8%  
Effective tax rate %31.117.6 177.1%   
Net profit margin %7.27.3 99.1%  
BALANCE SHEET DATA
Current assets Rs m6,41019,455 32.9%   
Current liabilities Rs m8,82810,076 87.6%   
Net working cap to sales %-23.028.6 -80.7%  
Current ratio x0.71.9 37.6%  
Inventory Days Days5898 58.9%  
Debtors Days Days3867 57.3%  
Net fixed assets Rs m1,40620,260 6.9%   
Share capital Rs m166252 65.8%   
"Free" reserves Rs m6,28626,633 23.6%   
Net worth Rs m6,45526,886 24.0%   
Long term debt Rs m02,340 0.0%   
Total assets Rs m8,82841,173 21.4%  
Interest coverage xNM13.1-  
Debt to equity ratio x00.1 0.0%  
Sales to assets ratio x1.20.8 149.1%   
Return on assets %8.66.4 134.4%  
Return on equity %11.88.9 132.0%  
Return on capital %17.110.8 158.7%  
Exports to sales %8.347.6 17.4%   
Imports to sales %21.014.9 141.5%   
Exports (fob) Rs m86915,642 5.6%   
Imports (cif) Rs m2,2094,884 45.2%   
Fx inflow Rs m95915,642 6.1%   
Fx outflow Rs m2,6124,884 53.5%   
Net fx Rs m-1,65310,759 -15.4%   
CASH FLOW
From Operations Rs m1,0703,411 31.4%  
From Investments Rs m-750-1,354 55.4%  
From Financial Activity Rs m-150-1,304 11.5%  
Net Cashflow Rs m171753 22.7%  

Share Holding

Indian Promoters % 0.0 45.9 -  
Foreign collaborators % 51.8 0.0 -  
Indian inst/Mut Fund % 18.2 11.4 159.6%  
FIIs % 1.0 25.3 4.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 29.1 17.4 167.2%  
Shareholders   28,591 36,892 77.5%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare MERCK LTD With:   CIPLA  PFIZER  ALKEM LABORATORIES  ASTRAZENECA PHARMA  STRIDES SHASUN LTD  

Compare MERCK LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

IPCA LABS Announces Quarterly Results (1QFY19); Net Profit Down 423.6% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, IPCA LABS has posted a net profit of Rs 655 m (down 423.6% YoY). Sales on the other hand came in at Rs 9 bn (up 19.8% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

MERCK LTD Announces Quarterly Results (1QFY19); Net Profit Up 63.1% (Quarterly Result Update)

Aug 8, 2018 | Updated on Aug 8, 2018

For the quarter ended June 2018, MERCK LTD has posted a net profit of Rs 328 m (up 63.1% YoY). Sales on the other hand came in at Rs 2 bn (down 17.1% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

MERCK LTD SHARE PRICE


Sep 21, 2018 03:37 PM

TRACK MERCK LTD

  • Track your investment in MERCK LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE MERCK LTD WITH

MARKET STATS